Johnson & Johnson Enters Binding Offer to Sell LifeScan, Inc. For Approx. $2.1 Billion
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.
Johnson & Johnson has received a binding offer from Platinum Equity to buy its LifeScan Business, which serves approximately 20 million patients globally in more than 90 countries. Platinum Equity is one of the leading private investment firms and LifeScan, Inc is a leader in blood glucose monitoring products. The offer is for approximately $2.1 billion and is subject to customary adjustments.
LifeScan realized 2017 net revenues of approximately $1.5 billion.
The end of the offer’s acceptance period will be on June 15, 2018, and if accepted is expected to close by the end of 2018.
To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.